Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00459186 · ClinicalTrials.gov registry record · Phase 1
The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT00459186 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 19 participants.
The verdict
NCT00459186, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and optimal dose of RAD001 and docetaxel plus prednisone in men with hormone refractory, metastatic prostate cancer (Phase I). Once an appropriate dose is reached, the purpose then will be to determine the response rate of docetaxel plus RAD001 (Phase II).
Interventions
- DRUG Docetaxel
- DRUG Prednisone
- DRUG RAD001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2005-11 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00459186
The ClinicalTrials.gov registry entry for NCT00459186 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT00459186 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00459186 about?
NCT00459186 is a clinical study titled "The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer". The purpose of this study is to evaluate the safety and optimal dose of RAD001 and docetaxel plus prednisone in men with hormone refractory, metastatic prostate cancer (Phase I). Once an appropriate dose is reached, the purpose then will be to determine the response rate of docetaxel plus RAD001 (P...
What is the current status of trial NCT00459186?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2005-11. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00459186?
The interventions under investigation include: Docetaxel (DRUG), Prednisone (DRUG), RAD001 (DRUG).
Who is sponsoring clinical trial NCT00459186?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.